The choice of model organism is central to the study’s design. The team used Drosophila melanogaster flies genetically modified to express human amyloid-beta 42, the sticky peptide that aggregates into the plaques characteristic of Alzheimer’s disease. Although flies are distant from humans on the evolutionary tree, they share a remarkable proportion of their genes with people, and many of the molecular pathways implicated in neurodegeneration, including oxidative stress responses, cholinergic signalling, and tau phosphorylation cascades, are conserved. Fruit flies also live for only weeks, which means researchers can observe the full course of a neurodegenerative process and test interventions across the lifespan in a matter of days, something impossible in rodent or human studies. In this experiment, the Alzheimer-model flies were treated with the Caralluma extract for fourteen days before being assessed.

The behavioural results were the most visible evidence of benefit. Flies carrying the human amyloid-beta 42 gene typically show progressive deterioration in climbing ability, a standard measure of locomotor function in fly neurodegeneration research, as well as impaired grooming and deficits in learning assays. Treated flies performed significantly better across these measures and lived longer than their untreated counterparts. The researchers used an aversive phototaxis suppression assay to probe learning and memory, a test that measures a fly’s ability to suppress its natural attraction to light when that light is paired with an unpleasant stimulus. Improved performance in this assay suggests that the extract protected cognitive function, not merely motor capacity, although the authors are careful to frame these as preliminary findings in an invertebrate system.

Beneath the behavioural improvements, the biochemical data pointed to a familiar theme in neurodegeneration research: oxidative stress. The brains of Alzheimer-model flies suffer from an excess of reactive oxygen species that damage lipids, proteins, and DNA. The team measured malondialdehyde, a breakdown product of lipid peroxidation that serves as a marker of oxidative damage, and found it reduced in treated flies. At the same time, levels of the antioxidants glutathione and superoxide dismutase, two of the cell’s primary defences against oxidative injury, were increased. This shift in the balance between oxidative damage and antioxidant capacity is consistent with a neuroprotective effect and aligns with the known chemistry of many plant-derived polyphenols, which can act as antioxidants directly and can also induce the cell’s own antioxidant defence systems.

Perhaps the most pharmacologically interesting finding concerned acetylcholinesterase, the enzyme that breaks down the neurotransmitter acetylcholine. Cholinergic neurons in the brain are among the earliest casualties of Alzheimer’s disease, and the loss of acetylcholine contributes substantially to the memory impairment that defines the condition. Four of the currently approved Alzheimer’s drugs, including donepezil and galantamine, work by inhibiting acetylcholinesterase to keep acetylcholine available for longer in the synaptic cleft. In the treated flies, acetylcholinesterase levels were significantly reduced, suggesting that the extract may reproduce, at least partially, the mechanism of existing symptomatic therapies through a natural product mixture.

The molecular layer of the study focused on tau, the microtubule-associated protein whose pathological tangles inside neurons form the second hallmark lesion of Alzheimer’s disease alongside amyloid plaques. Quantitative analysis showed that the fly equivalent of the tau gene, dTau, was downregulated in extract-treated flies compared with untreated Alzheimer-model flies. Because tau pathology correlates more closely with cognitive decline than amyloid burden in human disease, any intervention that reduces tau expression or the signalling that drives tau phosphorylation attracts considerable attention. The researchers propose that the extract may be acting upstream of tau through pathways that connect amyloid toxicity to tau dysfunction.

To explore those upstream connections, the team turned to molecular docking, a computational technique that predicts how well small molecules fit into the binding pockets of target proteins. They focused on two enzymes with central roles in Alzheimer’s biology: glycogen synthase kinase-3, known as GSK3, and beta-secretase 1, known as BACE1. GSK3 is the major kinase that phosphorylates tau in the brain, promoting its aggregation into tangles, and it also participates in inflammatory and apoptotic signalling. BACE1 is the enzyme that performs the first cut in the production of amyloid-beta from its parent protein, making it a prime drug target for reducing amyloid generation. Docking simulations suggested that several phytochemicals present in the extract interact favourably with both enzymes, with catechin, a flavonoid found in many plants, showing the most promising predicted binding profiles against GSK3 and BACE1 alike.

The authors are explicit that docking is a hypothesis-generating tool rather than proof of mechanism. Predicted binding energies do not confirm that catechin or any other constituent of the extract actually inhibits GSK3 or BACE1 inside a living organism, and the extract is a complex mixture whose active components and their concentrations remain to be fully characterised. The study also did not directly measure amyloid-beta deposition or tau phosphorylation in the fly brains, so the link between the observed gene expression changes and the actual pathological lesions of Alzheimer’s disease remains to be established. Direct target validation, the authors note, together with assessment of amyloid and tau pathology and studies in mammalian models, will be required before any therapeutic relevance can be claimed.

Even with those caveats, the study fills a genuine gap. Caralluma dalzielii has a long history of traditional use for neurological complaints in the region where it grows across the Sahel and West Africa, yet it had never previously been evaluated in an experimental model of Alzheimer’s disease. Its close relative Caralluma fimbriata has been studied mainly for appetite suppression, and the genus as a whole remains underexplored relative to its chemical richness. Plants in this group produce an array of pregnane glycosides, flavonoids, and other secondary metabolites, and the new findings suggest that some of these compounds may act on multiple nodes of the Alzheimer’s disease network simultaneously, a polypharmacology that single-target drugs often lack.

The research also demonstrates the continuing value of the humble fruit fly in early-stage drug discovery. A complete behavioural, biochemical, and molecular evaluation of a natural product extract was accomplished in a model system that is inexpensive, rapid, and free of the ethical and logistical constraints of vertebrate studies, supported by funding from Nigeria’s TETFund institutional research programme. For a disease that affects tens of millions of people worldwide and for which approved therapies offer only modest symptomatic benefit, the pipeline of candidate compounds needs every accessible entry point. The Nigerian team’s results do not amount to a treatment, and no one should interpret them as a recommendation to seek out the plant itself. What they provide is a rigorous preliminary signal, generated through a transparent and reproducible workflow, that Caralluma dalzielii deserves a place in the queue of natural products being screened for Alzheimer’s drug discovery. If catechin and its neighbours in the extract can be isolated, validated against GSK3 and BACE1 in vitro, and tested in mammalian models of the disease, this Sahelian succulent may yet contribute more to modern medicine than its traditional reputation alone ever suggested.

Subject of Research: Neuroprotective effects of Caralluma dalzielii extract in a transgenic Drosophila model of Alzheimer's disease

Article Title: Targeting Alzheimer’s disease pathways with Caralluma dalzielii: behavioural, biochemical, and molecular evidence from a transgenic Drosophila melanogaster model

Article References: Ugwah-Oguejiofor, C. J., Hassan, E., Yakubu, D., Ahmed, A. H., Almustapha, Z., & Imam, M. U. (2026). Targeting Alzheimer’s disease pathways with Caralluma dalzielii: behavioural, biochemical, and molecular evidence from a transgenic Drosophila melanogaster model. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05637-3

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05637-3

Keywords: Caralluma dalzielii, Alzheimer's disease, Drosophila melanogaster, amyloid-beta 42, tau, GSK3, BACE1, acetylcholinesterase, oxidative stress, catechin, phytochemicals, molecular docking

The research team, working at the Korea Research Institute of Bioscience and Bioscience-affiliated laboratories, took an approach that sidesteps a long-standing obstacle in the field. Bone marrow from children with Legg-Calvé-Perthes disease is scarce and difficult to study, and even when mesenchymal stromal cells, the body’s principal skeletal progenitors, are isolated from osteonecrotic bone, they carry the imprint of a diseased, inflamed, poorly perfused tissue environment. Any abnormality observed in such cells could reflect that hostile microenvironment rather than an intrinsic flaw. To separate the two, the researchers reprogrammed skin fibroblasts from two patients with the disease, and from a healthy donor, into induced pluripotent stem cells using a non-integrating Sendai virus system that delivers the reprogramming factors OCT4, SOX2, KLF4 and c-MYC. Because skin cells can be reset to an embryonic-like state and then steered into mesenchymal stem cells under identical, standardized conditions, any difference that emerges between patient-derived and healthy cells must be written into the cells themselves rather than imposed by the tissue around them.

The quality control on this cellular reset was rigorous. The resulting induced pluripotent stem cell lines formed compact colonies with the characteristic morphology of embryonic stem cells, stained strongly for alkaline phosphatase, and expressed the canonical pluripotency markers OCT4, NANOG, TRA-1-60, TRA-1-81, SSEA-3 and SSEA-4 at levels comparable across all three lines. Quantitative PCR confirmed expression of OCT4 and REX1 in the undifferentiated state, and when the cells were allowed to spontaneously differentiate into embryoid bodies, they activated ectodermal markers such as SOX1 and PAX6, mesodermal markers including HAND1 and PDGFRA, and endodermal markers SOX7 and AFP. Immunostaining for TUJ1, NESTIN, DESMIN, alpha-SMA, FOXA2 and SOX17 confirmed protein-level differentiation into all three germ layers, and teratoma assays in immunodeficient mice produced tissues representing ectoderm, mesoderm and endoderm. G-band karyotyping showed normal diploid chromosomes in every line, ensuring that any phenotype found later was not an artefact of culture stress or genomic instability.

With validated stem cell lines in hand, the team differentiated them into induced mesenchymal stem cells using a defined, xeno-free protocol, first patterning the cells toward the mesodermal lineage for four days and then maturing them for a further seventeen days on fibronectin-coated plates. Flow cytometry confirmed that the resulting cells expressed the canonical mesenchymal markers CD73 and CD105 and lacked the haematopoietic markers CD34 and CD45, consistent with bona fide MSC identity. One subtlety stood out: the two patient-derived lines expressed CD90, a surface glycoprotein involved in adhesion and MSC immunophenotype, at only about sixty to seventy percent of the level seen in healthy donor cells, which reached roughly ninety-five percent. Proliferation rates, however, were indistinguishable between the groups, meaning the patient cells grew normally even as they showed this subtle phenotypic deviation, hinting that the real differences lay deeper, in what the cells could become rather than how fast they could multiply.

What the cells could become turned out to be the central finding. Under osteogenic induction, healthy donor cells produced abundant mineralized matrix, revealed by intense Alizarin Red S staining, and strongly upregulated the osteoblast genes RUNX2 and BGLAP. Both patient-derived lines formed dramatically fewer mineral deposits and mounted only weak induction of the same genes. Adipogenesis fared no better: healthy cells accumulated plentiful lipid droplets stained by Oil Red O and induced the adipogenic regulators PPARG and ADIPOQ, while patient cells showed markedly reduced lipid accumulation and gene induction. Chondrogenesis, assessed by Alcian Blue staining of sulfated glycosaminoglycans and by expression of SOX9 and COL2A1, was also reduced but comparatively better preserved. Crucially, this pattern of a simultaneous, broad suppression of all three mesenchymal lineages argues against the classic idea of a simple lineage shift, in which bone-forming cells are diverted into fat cells. Instead, it points to a deeper loss of overall differentiation competence within the patient-derived progenitors themselves.

The molecular culprit emerged when the researchers examined the Wnt/beta-catenin pathway, the master regulator of mesenchymal lineage commitment. Beta-catenin, the transcriptional co-activator at the heart of canonical Wnt signalling, promotes osteogenesis and chondrogenesis while restraining adipogenesis, and its intracellular abundance is normally kept in check by glycogen synthase kinase-3, which phosphorylates beta-catenin and tags it for proteasomal destruction. In the patient-derived cells, the team found a striking double abnormality. Transcripts for CTNNB1, the gene encoding beta-catenin, were significantly reduced, while GSK3B mRNA was markedly elevated. At the protein level, phosphorylation of GSK3alpha at Tyr279 and GSK3beta at Tyr216, the modifications associated with enhanced enzymatic activity, was substantially increased, reaching roughly 1.8- to 2.2-fold above healthy donor levels in the more severely affected patient line. Total beta-catenin protein and intracellular beta-catenin fluorescence were correspondingly diminished, painting a coherent picture of a kinase pushed into overdrive and a key transcriptional regulator destroyed faster than it should be.

The disease signature extended into inflammation, a domain long suspected to matter in this condition because children with active disease show elevated IL-6 and HMGB1 in synovial fluid. Even without any inflammatory stimulus, the patient-derived mesenchymal cells expressed higher baseline levels of IL6, PTGS2 and CCL2, indicating a primed inflammatory state. When the cells were challenged with IL-1beta, the patient cells responded with larger fold increases in these cytokines than healthy cells, and the Wnt target genes AXIN2 and LEF1, already slightly reduced at baseline, were driven down even further. Western blotting showed that IL-1beta pushed GSK3 phosphorylation higher in patient cells than in controls while beta-catenin, already low, declined still more. These exaggerated responses persisted after osteogenic differentiation, where patient-derived osteoblasts displayed stronger NF-kappaB phosphorylation and greater degradation of its inhibitor I-kappa-B-alpha upon inflammatory stimulation. Transcriptomic sequencing reinforced the theme, revealing enriched alterations in inflammatory signalling, extracellular matrix organization and Wnt-related regulatory pathways in both patient fibroblasts and patient-derived mesenchymal cells, with upregulation of multiple extracellular Wnt antagonists including DKK1, SFRP1, SFRP2, WIF1 and SOST.

The most striking result, and the one with the clearest translational implication, came next. When the researchers treated the patient-derived cells with lithium chloride, a long-established inhibitor of GSK3, beta-catenin fluorescence recovered to levels comparable to untreated healthy donor cells, with the rescue being strongest precisely where the deficit had been greatest. More importantly, the functional defect yielded to the same treatment. Lithium chloride substantially increased mineralized nodule formation and Oil Red O staining in both patient lines during osteogenic and adipogenic induction, and quantitative PCR confirmed that either lithium chloride or the more selective inhibitor CHIR99021 significantly boosted expression of BGLAP, RUNX2, ADIPOQ and PPARG. The differentiation programs had not been deleted; they had merely been silenced by an overactive kinase, and silencing the kinase switched them back on. This established that the mesenchymal failure in Legg-Calvé-Perthes disease reflects a reversible, kinase-dependent signalling imbalance rather than irreversible cellular damage.

The study’s authors are careful to place their findings in context. Observations in patients, such as elevated circulating leptin and increased adipose tissue within the affected femoral head, reflect systemic and tissue-level changes that arise from ischemia, inflammation and altered marrow mechanics, and the in vitro reduction in adipogenesis seen here does not contradict that clinical picture. Rather, the platform isolates the intrinsic cellular component of the disease, complementing animal models in which ischemia was surgically induced in piglets and rodents. Those models have shown that ischemia activates hypoxia-inducible factor 1-alpha and drives inflammatory and angiogenic responses, and the new human data now connect those tissue-level events to a specific, druggable intracellular node inside the progenitors that must rebuild the bone. The authors propose a reciprocal feedback loop in which inflammatory activation sustains GSK3 activity, further destabilizing beta-catenin and progressively compromising skeletal regeneration.

For a disease whose current treatments range from conservative containment to major reconstructive surgery, the prospect of a pharmacological strategy that restores the bone-building capacity of a child’s own progenitor cells is genuinely exciting. Lithium is an old drug with a well-characterized safety profile in other contexts, and the iPSC-based model developed here provides a patient-specific testing ground for optimizing GSK3-targeted regenerative therapies before they reach the clinic. Much work remains, including validating the findings in larger patient cohorts and determining how a GSK3 inhibitor could be delivered safely to the developing femoral head. But the central message stands: the cellular failure underlying a devastating childhood hip disease is not a life sentence written into the genome, but a reversible regulatory state, and with the right key, the machinery of skeletal repair can be switched back on.

Subject of Research: Reversible GSK3/beta-catenin dysregulation in patient-derived iPSC-mesenchymal stem cells from children with Legg-Calvé-Perthes disease

Article Title: Patient‐Derived iPSC‐MSC Modelling Reveals Reversible GSK3‐Mediated Suppression of Mesenchymal Lineage Differentiation in Legg‐Calvé‐Perthes Disease

Article References: Seol, B., Lim, H. J., Song, C. L., Lee, J., & Cho, Y. S. (2026). Patient‐Derived iPSC ‐ MSC Modelling Reveals Reversible GSK3 ‐Mediated Suppression of Mesenchymal Lineage Differentiation in Legg‐Calvé‐Perthes Disease. Journal of Cellular and Molecular Medicine, 30(17), Article e71350. https://doi.org/10.1111/jcmm.71350

Image Credits: AI Generated

DOI: 10.1111/jcmm.71350

Keywords: Legg-Calvé-Perthes disease, induced pluripotent stem cells, mesenchymal stem cells, GSK3, beta-catenin, Wnt signalling, osteonecrosis, osteogenesis, inflammation, lithium chloride, CHIR99021, paediatric orthopaedics